ClinicalTrials.gg
RecruitingNCT07463937MTX-RWS-IUpdated Mar 11, 2026

A RWS of SC MTX in Chinese RA Patients

An observational study in Rheumatoid Arthritis (RA), sponsored by Peking University People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Peking University People's Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital — 5 open to participants now, 5 under way, none of them phase 3. Arthritis, Rheumatoid · Peking University People's Hospital.

Started
2024
with 1 other
Observational
4 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital, this one is one of 2 that started in 2024, is one of 4 observational ones, and was the 11th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Rheumatoid by Peking University People's Hospital, or all of them as a file.
02

Study summary

Design: A prospective, single-arm, multicenter, real-world study that does not interfere with the patient's treatment plan

Primary Objective:

1. To evaluate the effectiveness and safety of subcutaneous Methotrexate (MTX) in RA patients in a real-world setting;

Exploratory Objectives:

  1. To assess the safety and effectiveness of subcutaneous MTX in RA patients with interstitial lung disease (ILD) or interstitial lung abnormalities (ILAs), and stable coronary artery disease (SCAD) in a real-world setting;
  2. To evaluate the effectiveness and safety of subcutaneous MTX in RA patients with different clinical subtypes.

The study includes adult RA patients treated with subcutaneous MTX, divided into the following four cohorts based on comorbidities and clinical subtypes:

Cohort 1: Chinese RA patients receiving subcutaneous MTX treatment (8,000 cases) Cohort 2: Chinese RA patients with ILD or ILAs receiving subcutaneous MTX treatment (200 cases) Cohort 3: Chinese RA patients with clinical subtype results at enrollment, receiving subcutaneous MTX treatment (1,500 cases) Cohort 4: Chinese RA arthritis patients with SCAD receiving subcutaneous MTX treatment (300 cases)

03

Conditions studied

  • Rheumatoid Arthritis (RA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study includes adult RA patients treated with subcutaneous MTX.

Eligibility criteria

Inclusion Criteria:

  1. Adult patients diagnosed with rheumatoid arthritis according to the 1987 ACR or 2010 ACR/EULAR classification criteria.
  2. Patients who, after clinical evaluation, are starting or preparing to start subcutaneous methotrexate treatment, with expected benefits outweighing the risks.
  3. Patients who agree to participate in the study, can comply with follow-up, and sign the form.

Additionally, subjects meeting the following inclusion criteria can be assigned to Cohort 2:

Inclusion Criteria:

  1. Diagnosed with interstitial lung disease (ILD) or interstitial lung abnormalities (ILAs) prior to or at the time of enrollment;
  2. Have baseline forced vital capacity (FVC) results at the time of enrollment, with FVC being 50% or more of the predicted value.

Subjects meeting the following inclusion criteria can be assigned to Cohort 3:

1. Have a clear clinical subtype result at the time of enrollment.

Subjects meeting the following inclusion criteria can be assigned to Cohort 4:

  1. Diagnosed with stable coronary artery disease prior to or at the time of enrollment, including those with a history of coronary artery intervention or coronary artery bypass grafting for at least one year, or angiographic evidence of ≥50% stenosis in at least one coronary artery without the need for revascularization;
  2. C-reactive protein (CRP) or high-sensitivity CRP (hsCRP) ≥2 mg/L.

Exclusion Criteria:

  1. Pregnant or breastfeeding women;
  2. Serum creatinine: Female patients with serum creatinine >1.4 mg/dL (124 μmol/L); male patients with serum creatinine >1.6 mg/dL (141 μmol/L); patients with (ALT) or aspartate aminotransferase (AST) >1.5 times the (ULN);
  3. count \<80×10\^9/L; white blood cell (WBC) count \<3.5×10\^9/L; total >1.5 times the ULN;
  4. Presence of severe, uncontrolled comorbid conditions, such as (but not limited to) neurological, cardiovascular, hepatic, renal, gastrointestinal, or endocrine diseases, which in the investigator's judgment may interfere with the patient's participation in the study;
  5. Patients with a history of within the past 5 years;
  6. Cardiac diseases: decompensated heart failure or hypertension (hypertension that cannot be controlled to target levels of systolic and diastolic blood pressure despite lifestyle modifications and adequate doses of at least three antihypertensive drugs, including diuretics);
  7. Patients with significant or laboratory-confirmed immunodeficiency syndromes;
  8. Patients with severe acute or chronic infections;
  9. Patients with pre-existing hematologic disorders, such as myelodysplasia, leukopenia, thrombocytopenia, or anemia;
  10. Patients allergic to the study-related drug;
  11. Patients with a history of drug abuse, mental illness, or alcoholism, who cannot cooperate with clinical researchers;
  12. Other patients deemed unsuitable for participation in the study by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Cohort 1

    Chinese RA patients receiving subcutaneous MTX treatment (8,000 cases)

  • Cohort 2

    Chinese RA patients with ILD or ILAs receiving subcutaneous MTX treatment (200 cases)

  • Cohort 3

    Chinese RA patients with clinical subtype results at enrollment, receiving subcutaneous MTX treatment (1,500 cases)

  • Cohort 4

    Chinese RA arthritis patients with SCAD receiving subcutaneous MTX treatment (300 cases)

06

What researchers measure

Primary outcomes

  1. ACR20 response rate at 24 weeks

    The ACR20 involves following indicators: tender joint count (TJC, 68 major joints), swollen joint count (SJC, 66 major joints), Visual Analog Score for pain (VAS), Patient Global Assessment (PGA), Estimator Global Assessment (EGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Acute-Phase Reactant (Erythrocyte Sedimentation Rate or C-Reactive Protein). ACR20 response requires: ① ≥20% improvement in TJC; ② ≥20% improvement in SJC; ③ ≥20% improvement in 3 of following 5 indicators: VAS, PGA, EGA, HAQ-DI, Acute-Phase Reactant (ESR or CRP).

    Time frame: 24 weeks after enrollment

Secondary outcomes

  1. ACR20 response rate at 4 and 12 weeks

    The ACR20 involves following indicators: tender joint count (TJC, 68 major joints), swollen joint count (SJC, 66 major joints), Visual Analog Score for pain (VAS), Patient Global Assessment (PGA), Estimator Global Assessment (EGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Acute-Phase Reactant (Erythrocyte Sedimentation Rate or C-Reactive Protein). ACR20 response requires: ① ≥20% improvement in TJC; ② ≥20% improvement in SJC; ③ ≥20% improvement in 3 of following 5 indicators: VAS, PGA, EGA, HAQ-DI, Acute-Phase Reactant (ESR or CRP).

    Time frame: 4 and 12 weeks after enrollment

  2. ACR50 response rates at 4, 12, and 24 weeks

    The ACR50 involves following indicators: tender joint count (TJC, 68 major joints), swollen joint count (SJC, 66 major joints), Visual Analog Score for pain (VAS), Patient Global Assessment (PGA), Estimator Global Assessment (EGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Acute-Phase Reactant (Erythrocyte Sedimentation Rate or C-Reactive Protein). ACR50 response requires: ① ≥50% improvement in TJC; ② ≥50% improvement in SJC; ③ ≥50% improvement in 3 of following 5 indicators: VAS, PGA, EGA, HAQ-DI, Acute-Phase Reactant (ESR or CRP).

    Time frame: 4, 12, and 24 weeks after enrollment

  3. ACR70 response rates at 4, 12, and 24 weeks

    The ACR70 involves following indicators: tender joint count (TJC, 68 major joints), swollen joint count (SJC, 66 major joints), Visual Analog Score for pain (VAS), Patient Global Assessment (PGA), Estimator Global Assessment (EGA), Health Assessment Questionnaire-Disability Index (HAQ-DI), Acute-Phase Reactant (Erythrocyte Sedimentation Rate or C-Reactive Protein). ACR70 response requires: ① ≥70% improvement in TJC; ② ≥70% improvement in SJC; ③ ≥70% improvement in 3 of following 5 indicators: VAS, PGA, EGA, HAQ-DI, Acute-Phase Reactant (ESR or CRP).

    Time frame: 4, 12, and 24 weeks after enrollment

  4. Improvement in DAS28 scores at 4, 12, and 24 weeks compared to baseline.

    The DAS28 includes DAS28-ESR and DAS28-CRP. The DAS28-ESR score involves four indicators: tender joint count (TJC, 28 major joints), swollen joint count (SJC, 28 major joints), erythrocyte sedimentation rate (ESR), and patient global assessment (PGA). Calculation formula: DAS28-ESR (points) = 0.56√TJC28(points) + 0.28√SJC28(points) + 0.70×ln[ESR(mm/1h)]+ 0.014×[PGA (points)] The DAS28-CRP score involves four indicators: tender joint count (TJC, 28 major joints), swollen joint count (SJC, 28 major joints), C-Reactive Protein (CRP), and patient global assessment (PGA). Calculation formula: DAS28-CRP (points) = 0.56√TJC28(points) + 0.28√SJC28(points) + 0.36×ln[CRP(mg/L)]+ 0.014×[PGA (points)]+0.96

    Time frame: 4, 12, and 24 weeks after enrollment compared to baseline

  5. Improvement in CDAI scores at 4, 12, and 24 weeks compared to baseline

    The CDAI involves following indicators: tender joint count (TJC, 28 major joints), swollen joint count (SJC, 28 major joints), patient global assessment (PGA) and evaluator global assessment (EGA). Calculation formula: CDAI (points) = TJC28(points) + SJC28(points) + PGA (points) + EGA(points)

    Time frame: 4, 12, and 24 weeks after enrollment compared to baseline

  6. Improvement in patient global assessment (PGA), Visual Analog Score for pain (VAS), and evaluator global assessment (EGA) at 4, 12, and 24 weeks compared to baseline.

    Improvement in patient global assessment (PGA), Visual Analog Score for pain (VAS), and evaluator global assessment (EGA) at 4, 12, and 24 weeks compared to baseline.

    Time frame: 4, 12, and 24 weeks after enrollment compared to baseline

  7. Safety endpoints within 24 weeks, including the number and incidence of adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs).

    Safety endpoints within 24 weeks, including the number and incidence of adverse events (AEs), serious adverse events (SAEs), and adverse drug reactions (ADRs).

    Time frame: 4, 12, and 24 weeks after enrollment

Other outcomes

  1. The average decline in forced vital capacity (FVC) one year after enrollment compared to baseline (Cohort 2)

    The average decline in forced vital capacity (FVC) one year after enrollment compared to baseline

    Time frame: 1 year after enrollment compared to baseline

  2. Changes in the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) scores at 4 weeks, 12 weeks, 24 weeks, and one year after enrollment compared to baseline (Cohort 2)

    Changes in the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) scores at 4 weeks, 12 weeks, 24 weeks, and one year after enrollment compared to baseline

    Time frame: 4, 12, 24 weeks and 1 year after enrollment compared to baseline

  3. Time to the first acute exacerbation of interstitial lung disease (ILD) (Cohort 2)

    The definition of the first acute exacerbation of ILD will refer to the diagnostic criteria from the 2019 "Chinese Expert Consensus on the Diagnosis and Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis": unexplained worsening or dyspnea within the past 30 days; new diffuse pulmonary infiltrates or parenchymal abnormalities on chest Xray, high-resolution computed tomography (HRCT), or both since the last visit, without pneumothorax or pleural effusion; exclusion of any known causes of acute exacerbation, including infection, left heart failure, pulmonary embolism, and any identifiable causes of acute lung injury.

    Time frame: 4 weeks, 12 weeks, 24 weeks, and 1 year after enrollment compared to baseline

  4. Cohort 4 additional endpoints

    The number and proportion of various cardiovascular events occurring within two years (including but not limited to malignant arrhythmias, heart failure, uncontrolled blood pressure, hospitalization due to various cardiovascular diseases, cardiovascular disease-related death, acute myocardial infarction, unstable angina, ischemic stroke, and ischemia-induced coronary revascularization, as well as the occurrence, diagnosis, and treatment of these conditions)

    Time frame: 2 years after enrollment]

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jul 2027, 34 months after the start.

Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 34 months is below that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 11, 2026
StartActual
Sep 3, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07463937
Responsible party
Zhanguo Li (Director, Head of Rheumatology, Principal Investigator, Peking University People's Hospital) — Principal investigator
First posted
Mar 11, 2026
Start date
Sep 3, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 11, 2026

Study contacts

XU LIU, MD
Contact
liuxupkupku@163.com
010-88325223

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion